Pharma giant Bayer has announced that it will shift the focus of its drug research away from women’s health and towards neurology, rare diseases, and immunology. According to Reuters Stefan Oelrich, head of Bayer’s pharmaceuticals unit, stated that the company will no longer have an explicit focus on women’s health during research and clinical phases. However, Bayer, maker of the Yasmin brand…
Sumitovant Biopharma has completed its acquisition of Myovant Sciences in an all-cash deal valued at approximately $1.7 billion. The acquisition involved Sumitovant acquiring all outstanding shares of Myovant not already owned by Sumitovant. As a result, Myovant will be delisted from the New York Stock Exchange, and its shares will no longer be publicly traded. The two companies plan to combine their…
Chugai Pharmaceutical and Biofourmis have formed a partnership to develop digital solutions for pain management in patients with endometriosis. The companies have been working together since July 2020 to develop objective assessment of pain associated with the disease, which has resulted in the utilization of Biofourmis’ Biovitals platform for a biosensor and AI-based algorithm. Chugai, headquartered in Tokyo, is a research-based pharmaceutical…
Menopause is defined as the final menstrual period and is typically confirmed after a woman has missed her period for 12 consecutive months. Most women experience menopause between ages 40 and 58. An estimated 45 million women in the U.S. are approaching or in menopause, which results in a decrease in estrogen and other hormones. Hot flashes, vaginal dryness and loss of bone density are…
Male Contraceptive Initiative (MCI), a non-profit, has partnered with the pharmaceutical company Eppin Pharma to provide a Program Related Investment (PRI) of up to $800K to support clinical trial activities for the company’s novel short-term, non-hormonal oral male contraceptive pill. Eppin Pharma’s lead male contraceptive candidate is a small organic compound that binds to EPPIN, a protein on the surface of human…
About a year ago Celmatix, a New York-based pre-clinical stage biotech company focused on ovarian biology, announced, that a novel PCOS target identified as part of its five-year, multi-target alliance with Evotec, progressed into hit-identification. Today Celmatix announced that another milestone has been achieved in this alliance, as Evotec and Bayer AG are advancing a second drug program, centered around a novel Celmatix-identified drug target,…
Women’s health pharma company TherapeuticsMD has entered into definitive agreements to license its products to an affiliate of Mayne Pharma, an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products. TherapeuticsMD’s products are designed…
Sebela Pharmaceuticals is launching a new division of the company named Sebela Women’s Health along with the appointment of Kelly Culwell, MD, as Head of Research and Development for the division. Bringing more than twenty years’ experience in women’s health across public, private and non-profit organizations, Dr. Culwell joins the team when the company is in the final stages of clinical development of two…
